Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Leaflet CO-ATORIS 20mg / 10mg film-coated tablets
- Product code:
- W70918001
- Quantity:
- 10
- Indicated for:
- dyslipidemia
- Route of administration:
- oral
- Substance:
- atorvastatin + ezetimibe (statin lipid-lowering agent + lipid-lowering agent)
- ATC
- C10BA05 — Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Combinations of various lipid modifying agents
Precautions:
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myopathy / rhabdomyolysis
Seek medical advice if unexplained muscle pain occurs.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Pregnancy warning
Use during pregnancy only on medical advice.
The combination of atorvastatin and ezetimibe is used for the treatment of dyslipidemia, particularly in patients with primary or familial hypercholesterolemia. Atorvastatin is an HMG-CoA reductase inhibitor that reduces cholesterol synthesis in the liver, while ezetimibe inhibits cholesterol absorption in the intestine. Through their complementary actions, these medications significantly lower LDL cholesterol levels.
This combination is administered orally, usually once daily, with the dosage adjusted based on lipid levels and the patient's response to treatment. It is particularly indicated for patients who do not achieve lipid targets with statins alone or who require additional LDL cholesterol reduction.
Common side effects include headaches, fatigue, muscle pain, diarrhea, and nausea. In rare cases, severe adverse reactions such as rhabdomyolysis, hepatotoxicity, or pancreatitis may occur.
Patients taking this combination should undergo regular monitoring for liver function and lipid levels. The atorvastatin and ezetimibe combination provides an effective option for reducing cardiovascular risk, helping to prevent major cardiovascular events.
This combination is administered orally, usually once daily, with the dosage adjusted based on lipid levels and the patient's response to treatment. It is particularly indicated for patients who do not achieve lipid targets with statins alone or who require additional LDL cholesterol reduction.
Common side effects include headaches, fatigue, muscle pain, diarrhea, and nausea. In rare cases, severe adverse reactions such as rhabdomyolysis, hepatotoxicity, or pancreatitis may occur.
Patients taking this combination should undergo regular monitoring for liver function and lipid levels. The atorvastatin and ezetimibe combination provides an effective option for reducing cardiovascular risk, helping to prevent major cardiovascular events.
General data about CO-ATORIS 20mg / 10mg
- Substance:
- atorvastatin + ezetimibe
- Date of latest medicines list:
- 01-03-2025
- Product code:
- W70918001
- Concentration:
- 20mg / 10mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for atorvastatin + ezetimibe
- 20mg/10mg
- 40mg/10mg
- 80mg/10mg